Aastrom Biosciences Reports Third-Quarter 2014 Financial Results
13 nov. 2014 08h16 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences to Host Third Quarter 2014 Earnings Call on November 13, 2014
05 nov. 2014 16h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences Announces Plans to Change Name to Vericel Corporation and Move Headquarters to Cambridge, Massachusetts
09 oct. 2014 17h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Aastrom Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
17 sept. 2014 08h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences to Present Three-Year Data From the SUMMIT Extension Study of MACI(TM) at the 2015 American Academy of Orthopedic Surgeons Annual Meeting
16 sept. 2014 08h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences Announces Pricing of Public Offering of Common Stock
11 sept. 2014 08h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy
22 août 2014 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 22, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences Reports Second Quarter 2014 Financial Results
14 août 2014 07h30 HE
|
Aastrom Biosciences, Inc.
U.S. Commercial Business Generates Positive Contribution
Conference Call Today at 8:30 a.m. Eastern Time
ANN ARBOR, Mich., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc....
Aastrom Biosciences to Host Second Quarter 2014 Earnings Call on August 14, 2014
11 août 2014 09h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Announces Appointment of Zac Taylor as National Sales Director
14 juil. 2014 08h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., July 14, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...